SCHEMBL2649655

SCHEMBL2649655

CCO[C@H]1CC[C@H](NC2CCCCCC2)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.52
HSD17B10 Q99714 1/20 0.52
THRB P10828 1/20 0.47
ATM Q13315 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
KDM4E B2RXH2 2/20 0.34
MMP1 P03956 2/20 0.34
MMP2 P08253 1/20 0.34
EPHX1 P07099 2/20 0.33
ADH1B P00325 1/20 0.33
ADH1C P00326 1/20 0.33
ADH1A P07327 1/20 0.33
ADH4 P08319 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
SHBG P04278 1/20 0.33
NPC1 O15118 2/20 0.33
LMNA P02545 1/20 0.33
GAA P10253 1/20 0.33
MEN1 O00255 1/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2647838 1.00 ALDH1A1 (0.52) ALDH1A1HSD17B10THRBATML3MBTL1
SCHEMBL2647840 1.00 ALDH1A1 (0.52) ALDH1A1HSD17B10THRBATML3MBTL1
SCHEMBL2649659 1.00 ALDH1A1 (0.52) ALDH1A1HSD17B10THRBATML3MBTL1
SCHEMBL2648253 0.98 ALDH1A1 (0.48) ALDH1A1HSD17B10THRBATML3MBTL1
SCHEMBL2648256 0.98 ALDH1A1 (0.48) ALDH1A1HSD17B10THRBATML3MBTL1
SCHEMBL2648122 0.86 ALDH1A1 (0.46) ALDH1A1HSD17B10THRBATML3MBTL1
SCHEMBL2648807 0.86 ALDH1A1 (0.46) ALDH1A1HSD17B10THRBATML3MBTL1
SCHEMBL2648802 0.86 ALDH1A1 (0.46) ALDH1A1HSD17B10THRBATML3MBTL1
SCHEMBL2648124 0.86 ALDH1A1 (0.46) ALDH1A1HSD17B10THRBATML3MBTL1
SCHEMBL2648247 0.86 ALDH1A1 (0.46) ALDH1A1HSD17B10THRBATML3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7582769-B2 Dicycloalkyl urea glucokinase activators NOVO NORDISK A/S (DK) 2009-09-01 US disclosed
US-20090118501-A1 Dicycloalkyl Urea Glucokinase Activators NOVO NORDISK A/S (DK) 2009-05-07 US disclosed
EP-1904466-A1 DICYCLOALKYL UREA GLUCOKINASE ACTIVATORS Novo Nordisk A/S (DK) 2008-04-02 EP disclosed
WO-2007006760-A1 DICYCLOALKYL UREA GLUCOKINASE ACTIVATORS NOVO NORDISK A/S (DK) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118501-A1 Dicycloalkyl Urea Glucokinase Activators GCK, GCKR, UCK2 ALDH1A1 3782/4885HSD17B10 1699/4885THRB 2429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.